Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 11/20 | 1.00 |
| ▸ | ABCC8 | Q09428 | 11/20 | 1.00 |
| ▸ | KCNJ11 | Q14654 | 11/20 | 1.00 |
| ▸ | KCNJ8 | Q15842 | 11/20 | 1.00 |
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4256078 | 1.00 | ABCC9 (1.00) | ABCC9ABCC8KCNJ11KCNJ8GPR174 | |
| SCHEMBL29763183 | 1.00 | ABCC9 (1.00) | ABCC9ABCC8KCNJ11KCNJ8GPR174 | |
| SCHEMBL6926386 | 0.92 | ABCC9 (0.85) | ABCC9ABCC8KCNJ11KCNJ8GPR174 | |
| SCHEMBL7836158 | 0.92 | ABCC9 (0.84) | ABCC9ABCC8KCNJ11KCNJ8GPR174 | |
| SCHEMBL7098441 | 0.88 | ABCC9 (0.78) | ABCC9ABCC8KCNJ11KCNJ8GPR174 | |
| SCHEMBL6434255 | 0.88 | ABCC9 (0.77) | ABCC9ABCC8KCNJ11KCNJ8GPR174 | |
| SCHEMBL6905395 | 0.88 | ABCC9 (0.77) | ABCC9ABCC8KCNJ11KCNJ8GPR174 | |
| SCHEMBL6904767 | 0.84 | ABCC9 (0.72) | ABCC9ABCC8KCNJ11KCNJ8GPR174 | |
| SCHEMBL7095360 | 0.84 | ABCC9 (0.72) | ABCC9ABCC8KCNJ11KCNJ8GPR174 | |
| SCHEMBL5073035 | 0.83 | ABCC9 (0.71) | ABCC9ABCC8KCNJ11KCNJ8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004056181-A1 | ORGAN PRECONDITIONING, ARREST, PROTECTION, PRESERVATION AND RECOVERY (2) | GLOBAL CARDIAC SOLUTIONS PTY LTD (AU) | 2004-07-08 | — | — | WO | claimed |
| WO-2004056180-A1 | ORGAN PRECONDITIONING, ARREST, PROTECTION, PRESERVATION AND RECOVERY (1) | GLOBAL CARDIAC SOLUTIONS PTY LTD (AU) | 2004-07-08 | — | — | WO | claimed |
| EP-0539153-B1 | Acridine derivative as therapeutic agent | ZENECA LTD (GB) | 1997-04-23 | — | — | EP | claimed |
| US-5258390-A | Treatment of urinary incontinence | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-11-02 | — | — | US | claimed |
| EP-0539153-A1 | Acridine derivative as therapeutic agent | ZENECA LIMITED (GB) | 1993-04-28 | — | — | EP | claimed |
| JP-5201986-A | — | — | None | — | — | JP | disclosed |
| US-12605367-B2 | Methods of treatment and/or prevention of disorders and symptoms related to BKCa and/or SK channelophathies | Universite de Bordeaux (FR) | 2026-04-21 | — | — | US | disclosed |
| US-20220313664-A1 | METHODS OF TREATMENT AND/OR PREVENTION OF DISORDERS AND SYMPTOMS RELATED TO BKCA AND/OR SK CHANNELOPHATHIES | ASSETSUP (FR) | 2022-10-06 | — | — | US | disclosed |
| US-20220265282-A1 | USE OF REMOTE ISCHEMIC CONDITIONING FOR TRAUMATIC INJURY | THE HOSPITAL FOR SICK CHILDREN (CA) | 2022-08-25 | — | — | US | disclosed |
| EP-4031134-A1 | METHODS OF TREATMENT AND/OR PREVENTION OF DISORDERS AND SYMPTOMS RELATED TO BKCA AND/OR SK CHANNELOPHATHIES | UNIVERSITE DE BORDEAUX (FR) | 2022-07-27 | — | — | EP | disclosed |
| US-11045207-B2 | Use of remote ischemic conditioning for traumatic injury | THE HOSPITAL FOR SICK CHILDREN (CA) | 2021-06-29 | — | — | US | disclosed |
| WO-2021052952-A1 | METHODS OF TREATMENT AND/OR PREVENTION OF DISORDERS AND SYMPTOMS RELATED TO BKCA AND/OR SK CHANNELOPHATHIES | Universite de Bordeaux (FR) | 2021-03-25 | — | — | WO | disclosed |
| US-5455253-A | For urinary incontinence | ZENECA LIMITED (GB) | 1995-10-03 | — | — | US | disclosed |
| EP-0665834-A1 | QUINOLONE AND ACRIDINONE DERIVATIVES FOR THE TREATMENT OF URINARY INCONTINENCE | ZENECA LIMITED (GB) | 1995-08-09 | — | — | EP | disclosed |
| WO-1994008966-A1 | QUINOLONE AND ACRIDINONE DERIVATIVES FOR THE TREATMENT OF URINARY INCONTINENCE | ZENECA LIMITED (GB) | 1994-04-28 | — | — | WO | disclosed |
| US-5258390-A | Treatment of urinary incontinence | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-11-02 | — | — | US | disclosed |
| US-5258390-A | Treatment of urinary incontinence | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-11-02 | — | — | US | disclosed |
| JP-H05201986-A | THERAPEUTIC AGENT | IMPERIAL CHEM IND PLC <ICI> | 1993-08-10 | — | — | JP | disclosed |
| EP-0539153-A1 | Acridine derivative as therapeutic agent | ZENECA LIMITED (GB) | 1993-04-28 | — | — | EP | disclosed |
| EP-0539153-A1 | Acridine derivative as therapeutic agent | ZENECA LIMITED (GB) | 1993-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605367-B2 | Methods of treatment and/or prevention of disorders and symptoms related to BKCa and/or SK channelophathies | KCNN3, KCNN1, KCNN2 | ABCC9 1065/4885ABCC8 1310/4885KCNJ11 9/4885 |
| US-20220313664-A1 | METHODS OF TREATMENT AND/OR PREVENTION OF DISORDERS AND SYMPTOMS RELATED TO BKCA AND/OR SK CHANNELOPHATHIES | KCNN3, KCNN1, KCNN2 | ABCC9 2208/4885ABCC8 2726/4885KCNJ11 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.